Sharemaestro Newsreel

Bausch: Q2 Earnings Snapshot

Evolus Shareholder Alert

Faruqi & Faruqi, LLP, a securities law firm, is investigating potential claims against Evolus, Inc. following a federal securities class action lawsuit. The lawsuit alleges that Evolus made false statements regarding the origin of its Jeuveau™ product and misappropriated trade secrets from Medytox. This …

How Evolus Inc. (EOLS) Affects Rotational Strategy Timing

This article analyzes Evolus Inc. (EOLS) utilizing AI models to provide insights for a rotational strategy. It highlights a near-term strong sentiment challenging persistent mid and long-term weakness and identifies a significant risk-reward setup. The analysis offers three distinct institutional trading strategies—Position, Momentum Breakout, …

Haleon plc Revenue Breakdown – NYSE:HLN

Insider Selling: Liquidia (NASDAQ:LQDA) CAO Sells 1,600 Shares of Stock

Liquidia's Chief Accounting Officer, Dana Boyle, sold 1,600 shares of the company's stock for $140,048 on July 27th, 2026. This sale, executed under a Rule 10b5-1 plan, reduced her stake by 0.94% and was done to cover tax withholding obligations. The company's shares are …

Anika Therapeutics Inc (ANIK) Q2 2026 Earnings Call Highlights: Record Revenue and Margin ...

Anika Therapeutics Inc (ANIK) reported record Q2 2026 results, including a 17% increase in commercial channel revenue, a 65% gross margin, and record international revenue of $12.6 million. Adjusted EBITDA reached $7.1 million, and the company raised its full-year 2026 guidance. Despite these positive …

ANI Pharmaceuticals (NASDAQ: ANIP) insider plans Form 144 sale of restricted shares

ANI Pharmaceuticals insider Stephen P. Carey has filed a Form 144 to sell 6,163 shares of common stock, valued at $499,449.52. These shares originate from Restricted Stock Awards granted on April 6, 2019, and the sale is planned for July 29, 2026, on NASDAQ. …

Executive stock sale at Liquidia Corp (NASDAQ: LQDA) tied to RSU tax coverage

Liquidia Corp Chief Business Officer Jason Adair sold 688 shares of common stock on July 27, 2026, at $87.53 per share. This sale was conducted under a Rule 10b5-1 plan to cover taxes related to the settlement of previously granted Restricted Stock Units (RSUs). …

Lifecore Sets Aug. 5 Webcast for Second-Quarter Results

Lifecore Biomedical (NASDAQ: LFCR) announced it will report its second-quarter financial results for the period ended June 30, 2026, on Wednesday, August 5, 2026, before market open. Senior management will host a webcast at 8:00 a.m. Eastern Time to discuss the results, with an …

Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics will announce its second quarter 2026 financial results. The company will also hold a conference call and webcast to discuss these results and provide an update on recent business developments.

BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS, RAISES GUIDANCE

Second Quarter Consolidated Revenues of $2.85 billion, up 13% on a Reported basis and 11% on an Organic (non-GAAP)1 basis over the prior year period GAAP Net Income Attributable to Bausch Health of $258 million and GAAP Net Income of $260 million GAAP Earnings …

KNSA Maintained by Canaccord Genuity -- Price Target Raised to $98

BlackRock (NYSE: BLK) discloses 5.5% beneficial stake in Kiniksa (KNSA)

BlackRock, Inc. has disclosed a 5.5% beneficial ownership stake in Kiniksa Pharmaceuticals International, plc (KNSA) through a Schedule 13G filing. This amounts to 2,534,789 shares of Kiniksa's common stock, with BlackRock holding sole voting power over 2,470,912 shares and sole dispositive power over all …

Kiniksa Pharmaceuticals (KNSA) holder to sell 3,673 Class A shares under Rule 144

A holder of Kiniksa Pharmaceuticals (KNSA) Class A ordinary shares plans to sell 3,673 shares under Rule 144 through Charles Schwab & Co., Inc. The aggregate market value of these shares is $299,092.00, and they are listed on NASDAQ. The sale is related to …

Kiniksa Pharmaceuticals (KNSA) files Rule 144 notice for option and PSU/RSU shares

Kiniksa Pharmaceuticals International, plc has filed a Rule 144 notice for the potential sale of Class A Ordinary Shares. The filing indicates 45,049 shares linked to an employee stock option exercise from July 29, 2026, and 22,013 shares related to equity compensation (PSU/RSU) from …

Anika Therapeutics 2Q Adj EPS 42c >ANIK

This article reports that Anika Therapeutics' adjusted earnings per share (EPS) for the second quarter were 42 cents. The headline provides the key financial performance indicator for the company.

Teva Stock Rises After Earnings as Revenue Guidance Exceeds Expectations

Teva Pharmaceutical Industries' stock rose following its second-quarter earnings report. Investors focused on the company's updated full-year revenue guidance, which exceeded expectations, despite mixed earnings results.

BlackRock (PRGO holder) discloses 20.99M-share Perrigo stake on Schedule 13G/A

BlackRock, Inc. has filed an amended Schedule 13G/A, revealing a beneficial ownership of 20,988,733 shares of Perrigo Company plc common stock, which represents 15.2% of the class. The filing indicates BlackRock holds sole voting power over 20,758,891 shares and sole dispositive power over all …

BlackRock (LFCR holder) reports 2,010,546 Lifecore Biomedical shares in new ownership filing

BlackRock, Inc. has filed a Schedule 13G indicating a passive ownership stake in Lifecore Biomedical, Inc. (LFCR). BlackRock and its business units beneficially own 2,010,546 shares, representing 5.4% of Lifecore's common stock, with sole voting power over 1,988,535 shares and sole dispositive power over …

Tilray Q4: Dilution Outweighs Progress (NASDAQ:TLRY)

Tilray Brands experienced strong Q4 revenue growth, primarily due to the BrewDog acquisition. However, shares reached new lows due to ongoing dilution, and despite revenue gains, most segment gross margins stagnated, leading to a 60% year-over-year drop in adjusted net income. The company's valuation …

LNTH Maintained by Mizuho -- Price Target Lowered to $115

Mizuho maintained an "Outperform" rating for Lantheus Holdings (LNTH) but lowered its price target from $120 to $115. GuruFocus indicates that LNTH is currently 9.8% overvalued with a GF Value™ of $90.52 and a strong GF Score™ of 79/100, driven by high profitability and …

US FDA Closes Inspection of Alvotech's Manufacturing Facility in Iceland

Alvotech has announced the successful conclusion of a U.S. FDA inspection of its manufacturing facility in Reykjavik, Iceland, with no Form 483s issued. This positive outcome is a significant step for the company, as it addresses previous issues that had prevented the approval of …

Press Release: Anika Reports Second Quarter 2026 Financial Results

This press release from Anika reports their second quarter 2026 financial results. The document (although not provided) would contain key financial metrics and performance highlights for the period, offering insight into the company's fiscal health and operational achievements.

FDA issues Form 483 after Dr. Reddy’s (NYSE: RDY) plant inspection

Dr. Reddy’s Laboratories Limited announced that the USFDA completed a Pre-Approval Inspection (PAI) and Good Manufacturing Practices (GMP) inspection at its FTO-SEZ Process Unit-02 in Srikakulam, Andhra Pradesh, between July 20 and July 29, 2026. Following the inspection, the company received an FDA Form …

Teva Pharmaceutical Industries Sees Unusually High Options Volume (NYSE:TEVA)

Teva Pharmaceutical Industries (NYSE:TEVA) experienced an unusually high volume of call option trading, with 23,688 call options purchased, significantly above its daily average. This surge in options activity suggests increased bullish speculation, despite the company reporting mixed financial results with revenue exceeding estimates but …

TherapeuticsMD Inc (TXMD) Institutional Confidence

This article analyzes the institutional confidence in TherapeuticsMD Inc (TXMD), noting its current institutional shareholding score of 3.00, placing it 92nd out of 155 in the Pharmaceuticals industry. The institutional shareholding proportion has increased by 14.39% quarter-over-quarter to 32.99%. James Simons is identified as …

Karnataka discusses Takeda GCC expansion, innovation partnerships

Karnataka officials held discussions with Takeda Pharmaceutical leaders regarding the expansion of their Global Capability Centre (GCC) in Bengaluru. The talks focused on leveraging Karnataka's strong biotechnology and medtech ecosystems for digital transformation, research, and product development, including AI-driven drug discovery. Karnataka pledged continued …

Liquidia Corporation Q2 Results: Earnings date set for August 12, 2026

Liquidia Corporation announced it will release its second-quarter 2026 financial results on August 12, 2026. The biopharmaceutical company will host a live webcast at 8:30 a.m. ET to discuss its financial performance and provide a corporate update, focusing on products like YUTREPIA™ and the …

Dr. Reddy's launches sugammadex injection

Dr. Reddy's Laboratories Ltd. has launched sugammadex injection in the U.S., a generic version of Merck's Bridion, expanding its hospital portfolio. This launch aligns with the first day of generic availability and aims to provide affordable, high-quality medicines for reversing neuromuscular blockade during surgery. …

Amneal (AMRX) Reports Q2: Everything You Need To Know Ahead Of Earnings

Amneal (AMRX) Reports Q2: Everything You Need To Know Ahead Of Earnings Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be announcing earnings results this Thursday before market hours. Here's what to expect. Amneal beat analysts' revenue expectations last quarter, reporting revenues of $722.5 million, up …

Alkermes' Core Business Backed Q2 Beat, Orexin Pipeline to Serve as Catalyst, RBC Says

Alkermes' (ALKS) base business supported the company's Q2 beat, while its orexin pipeline serves as PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have …

Alvotech (NASDAQ:ALVO) Shares Up 13.5% - Here's What Happened

Alvotech (NASDAQ:ALVO) saw its shares climb 13.5% in mid-day trading but with significantly reduced volume. Analyst sentiment is mixed, with an average "Hold" rating and a target price of $7.60, as the company continues to report negative profitability despite $105.9 million in quarterly revenue. …

SCYX|SCYNEXIS Inc|Price:3.770|Chg%:+0.140

SCYNEXIS Inc. (SCYX) shows strong fundamentals, high growth potential, and is considered fairly valued within the Pharmaceuticals industry. Analysts have rated it as a "Buy" with a significant upside potential of 839.68%. The company is pioneering medicine for difficult-to-treat infections, with its antifungal platform …

Tilray Brands (NASDAQ:TLRY) Announces Quarterly Earnings Results

Tilray Brands (NASDAQ:TLRY) reported mixed quarterly earnings, missing EPS estimates significantly at ($0.43) per share against an expected ($0.0

Alvotech Marks Key Milestone As FDA Closes Inspection Of Reykjavik Facility; Stock Up

(RTTNews) - Alvotech (ALVO), a biotechnology company focused on developing and manufacturing biosimilar medicines, announced that the U.S. FDA has successfully closed its inspection of the company's manufacturing facility in Reykjavik, Iceland, conducted in May 2026. The FDA classified the site as Voluntary Action …

Elanco Animal Health (ELAN) Expected to Release Earnings on Wednesday

Elanco Animal Health (ELAN) is scheduled to release its Q2 2026 earnings before market open on Wednesday, August 5th. Analysts anticipate earnings of $0.28 per share and revenue of $1.3125 billion, aligning with the company's guidance of $0.250-$0.285 EPS. The company surpassed expectations in …